| Qulipta (atogepant) / AbbVie |
| Active, not recruiting | 3 | 1300 | Europe | 1. Chinese Generic Name: NA; English Generic Name: Atogepant; Brand Name: NA; 2. Chinese Generic Name: NA; English Generic Name: Atogepant; Brand Name: NA; 1. Chinese Generic Name: NA; English Generic Name: Atogepant placebo Tablets Clinical White; Brand Name: NA; 2. Chinese Generic Name: NA; English Generic Name: Atogepant placebo Tablets Clinical White; Brand Name: NA | AbbVie, AbbVie Inc. | Migraine | 07/25 | 11/26 | | |
| Active, not recruiting | 3 | 468 | Europe, Japan, US, RoW | Atogepant, Qulipta, Aquipta, Placebo for Atogepant | AbbVie, AbbVie Inc. | Menstrual Migraine (MM) | 06/26 | 07/27 | | |
CTR20250137: A study evaluating adverse events and changes in disease activity after oral administration of Atogepant in adult subjects with menstrual migraine. |
|
|
| Recruiting | 3 | 52 | China | 1. Chinese Generic Name: NA; English Generic Name: Atogepant Tablets; Brand Name: Qulipta?; 1. Chinese Generic Name: Placebo; English Generic Name: NA; Brand Name: NA | AbbVie Inc. / AbbVie Pharmaceuticals Trading (Shanghai) Co., Ltd. / Forest Laboratories Ireland Limited | Indications Menstrual migraine | | | | |
NCT03700320: Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine |
|
|
| Completed | 3 | 744 | US | Standard of Care (SOC) Migraine Preventive Medication, Atogepant | Allergan | Episodic Migraine | 05/20 | 05/20 | | |
ADVANCE, NCT03777059: 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine |
|
|
| Completed | 3 | 910 | US | Atogepant, Placebo | Allergan | Episodic Migraine | 06/20 | 06/20 | | |
|
|
NCT04961671: Effectiveness, Safety, and Tolerability of Analgesics in the Prevention of Chronic Migraine |
|
|
| Completed | 3 | 750 | RoW | atogepant, placebo | Peking University Third Hospital, Allergan Limited 1st Floor Marlow International, The Parkway Marlow, Buckinghamshire SL7 lYL | Chronic Migraine | 11/20 | 05/21 | | |
NCT03939312: Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine |
|
|
| Completed | 3 | 685 | US | Atogepant | Allergan | Episodic Migraine | 03/21 | 03/21 | | |
|
CTR20192279: Efficacy, safety, and tolerability of Atogepant in preventing chronic migraines |
|
|
| Completed | 3 | 135 | China | 1. Common Chinese name: atogepant tablets; 2. Common Chinese name: atogepant tablets; 1. Common Chinese name: placebo; 2. Common Chinese name: placebo | Allergan Pharmaceuticals International Limited / Forest Laboratories Ireland Limited / Allergan Sales, LLC / Allergan Information Consulting (Shanghai) Co., Ltd. | Indications: Prevention of chronic migraines | | | | |
| Completed | 3 | 778 | Europe, Canada, Japan, US, RoW | Atogepant 30 mg, Atogepant 60 mg, Placebo | Allergan | Chronic Migraine | 01/22 | 01/22 | | |
|
CTR20211591: Long-term safety study of Atogepant in Chinese participants with chronic migraine |
|
|
| Completed | 3 | 28 | China | 1. Chinese Generic Name: atogepant tablets; English Generic Name: atogepant tablets; Brand Name: NA; | Allergan Pharmaceuticals International Limited / Forest Laboratories Ireland Limited / Allergan Sales, LLC / Allergan Information Consulting (Shanghai) Co., Ltd. | Indications: Prevention of chronic migraines | | | | |
NCT04829747 / CTR20211591: Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine |
|
|
| Completed | 3 | 3 | RoW | Atogepant | Allergan | Chronic Migraine | 01/22 | 01/22 | | |
| Completed | 3 | 315 | Europe, Canada, US, RoW | Atogepant 60 mg, Placebo | Allergan | Episodic Migraine | 08/22 | 08/22 | | |
NCT04437433: A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine |
|
|
| Completed | 3 | 186 | Japan | Atogepant 60 mg | AbbVie | Chronic Migraine, Episodic Migraine | 06/24 | 06/24 | | |
| Completed | 3 | 596 | Europe, Canada, US, RoW | Atogepant 60 mg | AbbVie, AbbVie Inc. | Episodic Migraine, Chronic Migraine | 10/25 | 10/25 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Completed | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 05/25 | 05/25 | | |
Release, NCT05861427: Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine |
|
|
| Completed | 3 | 524 | Japan | Atogepant, Qulipta, Placebo for Atogepant | AbbVie | Migraine | 03/25 | 03/25 | | |
| Completed | 3 | 545 | Europe, Canada, RoW | Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate | AbbVie, AbbVie Inc. | Migraine | 04/25 | 06/26 | | |
NCT05711394 / 2022-501100-94-00: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant | AbbVie, AbbVie Inc. | Episodic Migraine | 03/28 | 05/28 | | |
NCT05707949 / 2022-501099-24-00: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine |
|
|
| Enrolling by invitation | 3 | 650 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689 | AbbVie, AbbVie Inc. | Migraine | 04/32 | 04/32 | | |
NCT06810505 / 2024-513836-28-00: A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years |
|
|
| Recruiting | 3 | 420 | Europe, Canada, Japan, US | Atogepant, Qulipta, Aquipta, Placebo for Atogepant | AbbVie, AbbVie Inc. | Chronic Migraine | 03/31 | 03/31 | | |
NCT02848326: Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention |
|
|
| Completed | 2/3 | 834 | US | Atogepant, AGN-241689, Placebo-matching Atogepant | Allergan | Migraine, With or Without Aura | 04/18 | 04/18 | | |
| Completed | 2/3 | 382 | Europe | Atogepant | AbbVie Deutschland GmbH & Co. KG, AbbVie Inc. | Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine) | | | | |
M24-305, 2023-506029-12-00: Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerability, and the Consistency of Effect of Atogepant for the Acute Treatment of Migraine (ECLIPSE) |
|
|
| Active, not recruiting | 2/3 | 1063 | Europe | Placebo for atogepant tablets 60mg, Atogepant | AbbVie Deutschland GmbH & Co. KG, AbbVie Inc. | Migraine | | | | |
TEMPLE, 2022-501172-25-00: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine |
|
|
| Active, not recruiting | 2/3 | 475 | Europe | Placebo for atogepant tablets 60mg, TOPIRAMATE, Atogepant, Placebo for topiramate capsules 25mg and 50mg | Abbvie Deutschland GmbH & Co. KG, AbbVie Inc. | Chronic and Episodic Migraine | | | | |
M24-859, 2024-512946-41-00: A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine |
|
|
| Active, not recruiting | 2/3 | 265 | Europe | Atogepant, Placebo for Atogepant | AbbVie Deutschland GmbH & Co. KG, AbbVie Inc. | Menstrual Migraine | | | | |
M21-199, 2022-501099-24-00: Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine |
|
|
| Recruiting | 2/3 | 102 | Europe | Atogepant | Abbvie Deutschland GmbH & Co. KG, AbbVie Inc. | Migraine | | | | |
M23-712, 2024-513836-28-00: A Study to Assess the Adverse Events and Change in Disease Activity of Atogepant Oral Tablets in Pediatric Participants with Chronic Migraine |
|
|
| Recruiting | 2/3 | 120 | Europe | Placebo for Atogepant, Atogepant | AbbVie Deutschland GmbH & Co. KG, AbbVie Inc. | Chronic Migraine | | | | |
